Its dividend: The stock recently yielded a whopping 7.3%. That's hard to beat and will generate around $730 for every $10,000 ...

BMY is looking to expand its pipeline/portfolio as the legacy portfolio is being adversely impacted due to continued generic ...

Pfizer reported a strong sales performance for its antifungal drug Cresemba in the Asia Pacific and China, thanks to a ...

Pfizer Inc. closed 26.70% short of its 52-week high of $31.54, which the company achieved on July 30th.

Pfizer (NYSE:PFE) announced robust sales for the antifungal drug Cresemba in partnership with Basilea Pharmaceutica Ltd, ...

A volatile stock market represents an ideal opportunity for long-term investors to pounce.

Pfizer’s stock has dropped 25% from its recent high, raising questions about whether it's a buy at $23. Pipeline failures and ...

PFE stock offers high dividend yields supported by cost optimizations and R&D. Discover its potential amid COVID-19 sales ...

Despite recent declines, we believe Pfizer stock is a compelling buy right now, with its current price of around $23 likely ...

Pfizer halted its oral obesity drug, danuglipron, in April 2025 due to liver injury concerns, a major pipeline setback. Find ...

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest ...